-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D0w2hRFeFA7uEniH+tIolda7/8f8dGonEZtnnFoRkiCtMgHweGlktOhUgc2bi5M1 h0GYHRdQHoxAGJESOjflIA== 0000950005-97-000279.txt : 19970222 0000950005-97-000279.hdr.sgml : 19970222 ACCESSION NUMBER: 0000950005-97-000279 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970214 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELLEGY PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-45279 FILM NUMBER: 97535281 BUSINESS ADDRESS: STREET 1: 1065 E HILLSDALE BLVD STREET 2: SUITE 418 CITY: FORSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 4153826770 MAIL ADDRESS: STREET 1: 1065 E HILLSDALE BLVD STREET 2: SUITE 418 CITY: FORSTER CITY STATE: CA ZIP: 94404 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SUNDANCE VENTURE PARTNERS LP CENTRAL INDEX KEY: 0000849512 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 680173342 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: C/O ANDERSON WELLS CO STREET 2: 400 E VAN BUREN ST #750 CITY: PHOENIX STATE: AZ ZIP: 85004 BUSINESS PHONE: 6022523441 MAIL ADDRESS: STREET 1: ANDERSON & WELLS CO STREET 2: 400 E VAN BUREN ST CITY: PHOENIX STATE: AZ ZIP: 85004 SC 13G 1 FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Cellegy Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 15115L-10-3 - -------------------------------------------------------------------------------- (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 9 Pages SCHEDULE 13G - ----------------------------------------------- --------------------------------------------- CUSIP No. 15115L-10-3 Page 2 of 9 Pages ------------------------ ----------- ----------- - ----------------------------------------------- --------------------------------------------- - --------- -------------------------------------------------------------------------------------------------------- NAMES OF REPORTING PERSONS 1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Sundance Venture Partners, L.P. - --------- -------------------------------------------------------------------------------------------------------- CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2 (a) |_| (b) |X| - --------- -------------------------------------------------------------------------------------------------------- 3 SEC USE ONLY - --------- -------------------------------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - --------- -------------------------------------------------------------------------------------------------------- 5 SOLE VOTING POWER NUMBER -0- OF ------- ------------------------------------------------------------------------------ SHARES 6 SHARED VOTING POWER BENEFICIALLY 583,482 OWNED ------- ------------------------------------------------------------------------------ BY 7 SOLE DISPOSITIVE POWER EACH -0- REPORTING ------- ------------------------------------------------------------------------------ PERSON 8 SHARED DISPOSITIVE POWER WITH 583,482 - --------------------------- ------- ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 583,482 - --------- -------------------------------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |_| - --------- -------------------------------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.3% - --------- -------------------------------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON PN - --------- --------------------------------------------------------------------------------------------------------
Page 2 of 9 Pages SCHEDULE 13G - ----------------------------------------------- --------------------------------------------- CUSIP No. 15115L-10-3 Page 3 of 9 Pages ------------------------ ----------- ----------- - ----------------------------------------------- --------------------------------------------- - --------- -------------------------------------------------------------------------------------------------------- NAMES OF REPORTING PERSONS 1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Anderson & Wells Company - --------- -------------------------------------------------------------------------------------------------------- CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2 (a) |_| (b) |X| - --------- -------------------------------------------------------------------------------------------------------- 3 SEC USE ONLY - --------- -------------------------------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - --------- -------------------------------------------------------------------------------------------------------- 5 SOLE VOTING POWER NUMBER -0- OF ------- ------------------------------------------------------------------------------ SHARES 6 SHARED VOTING POWER 583,482 BENEFICIALLY Anderson & Wells Company is the sole General Partner of Sundance Venture Partners, L.P. OWNED ------- ------------------------------------------------------------------------------ BY 7 SOLE DISPOSITIVE POWER EACH -0- REPORTING ------- ------------------------------------------------------------------------------ PERSON 8 SHARED DISPOSITIVE POWER 583,482 WITH Anderson & Wells Company is the sole General Partner of Sundance Venture Partners, L.P. - --------------------------- ------- ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 583,482 - --------- -------------------------------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |_| - --------- -------------------------------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.3% - --------- -------------------------------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON CO - --------- --------------------------------------------------------------------------------------------------------
Page 3 of 9 Pages Item 1. (a) Name of Issuer: Cellegy Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices: 1065 East Hillsdale Blvd., Suite 418, Foster City, CA 94404 Item 2. (a) Name of Person Filing: Sundance Venture Partners, L.P. (b) Address of Principal Business Office: 10600 N. DeAnza Boulevard, Suite 215, Cupertino, CA 95014 (c) Citizenship: U.S.A. (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 15115L-10-3 Item 3. Not applicable. Item 4. Ownership (a) Amount Beneficially Owned: 583,482 (b) Percent of Class: 11.3% (c) Number of shares as to which such person has: (i) sole power to vote or direct the vote: -0- (ii) shared power to vote or direct the vote: 583,482 (iii) sole power to dispose or to direct the disposition of: -0- (iv) shared power to dispose or to direct the disposition of: 583,482 Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not applicable Page 4 of 9 Pages Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not applicable. Item 8. Identification and Classification Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. Page 5 of 9 Pages Item 1. (a) Name of Issuer: Cellegy Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices: 1065 East Hillsdale Blvd., Suite 418, Foster City, CA 94404 Item 2. (a) Name of Person Filing: Anderson & Wells Company (General Partner of Sundance Venture Partners, L.P.) (b) Address of Principal Business Office: 400 East Van Buren, Suite 750, Phoenix, AZ 85004 (c) Citizenship: U.S.A. (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 15115L-10-3 Item 3. Not applicable. Item 4. Ownership (a) Amount Beneficially Owned: 583,482 (b) Percent of Class: 11.3% (c) Number of shares as to which such person has: (i) sole power to vote or direct the vote: -0- (ii) shared power to vote or direct the vote: 583,482 (iii) sole power to dispose or to direct the disposition of: -0- (iv) shared power to dispose or to direct the disposition of: 583,482 Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not applicable Page 6 of 9 Pages Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not applicable. Item 8. Identification and Classification Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. Page 7 of 9 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 13, 1997 SUNDANCE VENTURE PARTNERS, L.P. By: /s/ Larry J. Wells ------------------- Larry J. Wells ANDERSON & WELLS COMPANY By: /s/ Larry J. Wells ------------------- Larry J. Wells See attached Exhibit A Page 8 of 9 Pages EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that they are filing jointly, pursuant to Rule 13d-1 of the Securities Exchange Act of 1934 the statement dated February 13, 1997, containing the information required by Schedule 13G, for the 583,482 shares of the Common Stock of Cellegy Pharmaceuticals, Inc. held by Sundance Venture Partners, L.P. and Anderson & Wells Company, the sole General Partner of Sundance Venture Partners, L.P. Dated: February 13, 1997 SUNDANCE VENTURE PARTNERS, L.P. By: /s/ Larry J. Wells ------------------- Larry J. Wells ANDERSON & WELLS COMPANY By: /s/ Larry J. Wells ------------------- Larry J. Wells Page 9 of 9 Pages -----END PRIVACY-ENHANCED MESSAGE-----